Compare Novo Nordisk A/S (NVO) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Wynn Resorts, Limited — how do they compare? Novo Nordisk A/S trades at $38.6 (market cap $165.31B), while Wynn Resorts, Limited trades at $75.33 (market cap $7.75B). The key difference: Novo Nordisk A/S is far larger — about 21.3× Wynn Resorts, Limited's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Wynn Resorts, Limited for 76 Days on average.
| NVO | WYNN | |
|---|---|---|
Market Cap | $165.31B | $7.75B |
Volume | 11,432,838 | 2,243,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $133.09 |
52-Week Low | $35.29 | $74.97 |
Typical Hold Time | 116 Days | 76 Days |
Enterprise Value | $179.56B | $17.99B |
Dividend Yield | 4.71% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Wynn Resorts (WYNN) trades at $75.15, up 0.24% on the day, with a bearish technical signal driven by moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but showing margin pressure in the U.S. Revenue growth is supported by Macau strength, though high capital expenditure for new projects in the UAE and elevated debt levels present financial risks. Analyst consensus remains strongly bullish with a $132.36 price target, but recent institutional activity shows mixed positioning.
The outlook for WYNN hinges on Macau recovery and successful execution of expansion projects, offering potential upside from current levels. However, risks include rising capex, competitive pressures, and macroeconomic sensitivity. Investors should weigh strong analyst sentiment against fundamental challenges and debt load.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
